Rallybio Corp 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Rallybio Corp (RLYB) on June 29, 2023, reporting events occurring on June 28, 2023. The filing details significant changes to the company's executive leadership and Board of Directors, effective August 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Executive Leadership Transition: Stephen Uden, M.D., currently President and COO, was appointed Chief Executive Officer (CEO), effective August 1, 2023. He will retain his title as President.
- Chairman Transition: Martin Mackay, Ph.D., the current CEO and Chairman, was appointed Executive Chairman, effective August 1, 2023. He will remain a full-time employee focusing on strategy and investor relations.
- Board Expansion: The Board of Directors increased its size from ten to eleven members. Dr. Uden was appointed as a Class II director to fill the new vacancy, with a term expiring at the 2026 annual meeting. He will not receive additional compensation for this director role.
Compensation, Guidance, and Risks
Both executives entered into Second Amended and Restated Employment Agreements with the following terms:
- Base Salary: $530,000 annually for both Dr. Uden and Dr. Mackay.
- Target Bonus: 45% of annual base salary for both, contingent on performance goals.
- Contract Terms: Dr. Uden's agreement has an initial one-year term with automatic annual extensions. Dr. Mackay's agreement has an initial three-year term.
- Severance Provisions:
- Termination without cause/Good reason: 12 months of base salary, unpaid bonus, and 12 months of health premiums.
- Death/Disability: 6 months of base salary and unpaid bonus.
- Change in Control: 1.5 times the sum of base salary and target bonus payable over 18 months, plus 18 months of health premiums.
Equity awards based on time vesting will fully vest upon a change in control, subject to continued employment. The filing does not contain forward-looking guidance, risk factors, or unusual items beyond the standard employment contract contingencies.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 1, 2023).
- Review the full text of the Second Amended and Restated Employment Agreements expected in the Q2 2023 Form 10-Q.
- Confirm the impact of the leadership change on the company's strategic direction and investor relations focus.
- Monitor the Board composition changes and the new director term expiration (2026).